|
|
Article: Barr Launches Generic ACTIQ(R) Cancer Pain Management Product.
- Article from:
- PR Newswire
- Article date:
- September 27, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WOODCLIFF LAKE, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. announced that its subsidiary, Barr Laboratories, Inc., has today launched a generic version of Cephalon Inc.'s ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg, and 1600 mcg cancer pain management treatment product. Barr launched the product under the terms of a License Agreement previously granted to Barr by Cephalon in August 2004, pursuant to a Federal Trade Commission Order. The license grants Barr a non-exclusive right to sell a generic version of ACTIQ. Under the obligations of the agreement, Cephalon is currently supplying Barr ...